Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma
-
- STATUS
- Recruiting
-
- End date
- Jun 26, 2026
-
- participants needed
- 100
-
- sponsor
- The First Affiliated Hospital with Nanjing Medical University
Summary
PurposeTo evaluate whether immediate multiparametric MRI evaluate the sensitivity of modified neoadjuvant chemotherapy early in patient with muscle invasive bladder cancerMIBC.
RationaleMultiparametric MRI may help detect the early changes of bladder cancer receiving neoadjuvant chemotherapy.
Description
Objective
Primary: To evaluate whether multiparametric MRI can determine the sensitivity of modified neoadjuvant chemotherapy early in patient with muscle invasive bladder cancerMIBC.
SecondaryTo determine whether multiparametric MRI can predict the prognosis of modified neoadjuvant chemotherapy early in patient with muscle invasive bladder cancer.
Patients may receive neoadjuvant chemotherapy (typically three 21-day courses of modified gemcitabine-cisplatin(GC) therapy) followed by radical cystectomy and lymph node dissection.
Patients with primary bladder cancer or recurrence which is confirmed by pathology of previous biopsy or TURBT, undergo a multiparametric MRI(mpMRI) at baseline to stage the primary tumor. The mpMRI includes T2-weighted MRI, diffusion-weighted imaging, and dynamic contrast enhancement, which will be given a five-point VI-RADSVesical Imaging-Reporting And Data System score by two radiologists specialized in urogenital radiology. Patients considered NMIBCNon-muscle invasive bladder cancer with mpMRI will be given TURBT, while patients with MIBCMuscle invasive bladder cancerwill receive radical cystectomy and lymph node dissection after three 21-day courses of modified gemcitabine-cisplatin neoadjuvant chemotherapy. Patients also undergo an immediate mpMRI scan after one, two, and three cycles of neoadjuvant chemotherapy.
Specimens from the radical cystectomy are then examined by the pathology department as standard routine.
Details
| Condition | urinary tract neoplasm, Urologic Cancer, bladder cancer, bladder cancer, Bladder Carcinoma, Urothelial Cancer, bladder disorder, Bladder Disorders, Urothelial Cancer, Bladder Disorders, Bladder Carcinoma, Urologic Cancer, carcinoma of the bladder, bladder tumor |
|---|---|
| Treatment | Chemotherapy, Cystectomy and Lymphadenectomy, Immediate Multiparametric MRI, conventional Multiparametric MRI, Baseline Multiparametric MRI |
| Clinical Study Identifier | NCT04588168 |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Last Modified on | 26 January 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer